Immuneering Corporation (NASDAQ:IMRX) Sees Significant Growth in Short Interest

17 Jan 2026, 14:19 by Amy Steele · The Cerbat Gem

Immuneering Corporation (NASDAQ:IMRX – Get Free Report) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totaling 10,924,303 shares, an increase of 43.1% from the December 15th total of 7,635,854 shares. Based on an average trading volume of 1,780,211 shares, the days-to-cover ratio is currently 6.1 days. Approximately 21.9% of the company’s shares are short sold. Approximately 21.9% of the company’s shares are short sold. Based on an average trading volume of 1,780,211 shares, the days-to-cover ratio is currently 6.1 days.

Insider Buying and Selling

In other Immuneering news, Director Peter Feinberg bought 20,000 shares of the company’s stock in a transaction on Monday, January 12th. The stock was bought at an average price of $4.35 per share, for a total transaction of $87,000.00. Following the transaction, the director owned 135,441 shares of the company’s stock, valued at approximately $589,168.35. The trade was a 17.32% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Over the last three months, insiders have acquired 24,924 shares of company stock worth $108,400. 22.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Immuneering

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in Immuneering by 2.0% during the 2nd quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock worth $776,000 after purchasing an additional 4,458 shares in the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in shares of Immuneering during the third quarter worth about $35,000. Future Financial Wealth Managment LLC bought a new position in shares of Immuneering during the third quarter worth about $35,000. Dimensional Fund Advisors LP raised its position in Immuneering by 46.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 19,562 shares of the company’s stock valued at $137,000 after buying an additional 6,196 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV bought a new stake in Immuneering in the 3rd quarter valued at approximately $70,000. 67.65% of the stock is owned by institutional investors and hedge funds.

Immuneering Stock Down 1.3%

Shares of IMRX traded down $0.06 on Friday, hitting $4.58. The company’s stock had a trading volume of 1,571,991 shares, compared to its average volume of 3,135,325. The firm’s fifty day moving average price is $6.37 and its 200-day moving average price is $5.78. Immuneering has a fifty-two week low of $1.10 and a fifty-two week high of $10.08. The firm has a market capitalization of $295.73 million, a price-to-earnings ratio of -2.57 and a beta of 0.48.

Immuneering (NASDAQ:IMRX – Get Free Report) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). As a group, equities analysts predict that Immuneering will post -1.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on IMRX. Wall Street Zen downgraded Immuneering from a “hold” rating to a “sell” rating in a report on Saturday, December 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immuneering in a research note on Monday, December 29th. Chardan Capital reissued a “buy” rating and set a $20.00 price objective on shares of Immuneering in a research note on Thursday, November 13th. HC Wainwright restated a “buy” rating and set a $11.00 price objective on shares of Immuneering in a report on Tuesday, September 30th. Finally, Leerink Partners initiated coverage on shares of Immuneering in a research note on Friday, October 31st. They issued an “outperform” rating and a $15.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $16.50.

Check Out Our Latest Report on IMRX

Immuneering Company Profile

(Get Free Report)

Immuneering (Nasdaq: IMRX) is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering’s machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company’s AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.